Scarica l'app Stockscreener
293.86
0.48%
-1.41
Dopo l'orario di chiusura:
293.86
Precedente Chiudi:
$295.27
Aprire:
$295.27
Volume 24 ore:
114.17K
Relative Volume:
0.48
Capitalizzazione di mercato:
$32.66B
Reddito:
$5.36B
Utile/perdita netta:
$287.73M
Rapporto P/E:
116.48
EPS:
2.5229
Flusso di cassa netto:
$924.18M
1 W Prestazione:
-2.31%
1M Prestazione:
-4.73%
6M Prestazione:
-5.35%
1 anno Prestazione:
+14.95%
Intervallo 1D:
$291.66
$297.62
Intervallo di 1 settimana:
$289.54
$305.63
Portata 52W:
$218.31
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Nome
Beone Medicines Ltd Adr
Settore
Industria
Telefono
41-616851900
Indirizzo
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.81B | 5.36B | 287.73M | 924.18M | 2.5229 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 108.71B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 74.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.61B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 41.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Outperform |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Barclays | Overweight |
| 2025-04-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-12-03 | Ripresa | Morgan Stanley | Overweight |
| 2024-09-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-06 | Ripresa | JP Morgan | Overweight |
| 2023-09-12 | Iniziato | Macquarie | Outperform |
| 2023-08-17 | Iniziato | Jefferies | Buy |
| 2023-07-17 | Iniziato | Citigroup | Buy |
| 2023-06-30 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Iniziato | Daiwa Securities | Buy |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-10-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Ripresa | JP Morgan | Overweight |
| 2022-03-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Iniziato | Deutsche Bank | Buy |
| 2021-10-12 | Iniziato | Bernstein | Outperform |
| 2021-10-06 | Aggiornamento | CLSA | Underperform → Buy |
| 2021-03-08 | Iniziato | China Renaissance | Buy |
| 2021-03-01 | Downgrade | CLSA | Outperform → Underperform |
| 2020-11-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-06 | Downgrade | Piper Sandler | Neutral → Underweight |
Mostra tutto
Beone Medicines Ltd Adr Borsa (ONC) Ultime notizie
BeOne Medicines Ltd.Sponsored ADR $ONC Stock Position Raised by Slow Capital Inc. - MarketBeat
Chan Henry Lee Sells 332 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
RBC Capital Adjusts Price Target on BeOne Medicines to $423 From $425, Maintains Outperform Rating - Moomoo
A Look At BeOne Medicines (ONC) Valuation After New Coverage And FDA Orphan Drug Designation - Sahm
BeOne Medicines (NASDAQ:ONC) Stock Price Down 6.2%Here's Why - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Up – Here’s Why - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap UpTime to Buy? - MarketBeat
JPMorgan Chase & Co. Sells 47,002 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors - GlobeNewswire Inc.
Brokerages Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $401.00 - Defense World
Jain Global LLC Sells 32,244 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 341 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
Capital International Investors Boosts Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital International Sarl Has $50.61 Million Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital Group Private Client Services Inc. Reduces Stock Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Pinpoint Asset Management Singapore Pte. Ltd. Has $1.49 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (ONC) Is Down 15.1% After Surging To GAAP Profitability And Raising 2026 GuidanceHas The Bull Case Changed? - Sahm
JPMorgan Chase & Co. Has $16.63 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
TD Asset Management Inc Takes $9.33 Million Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Price Target Raised to $410.00 - Defense World
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment - Finviz
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
Generali Investments Management Co LLC Takes Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Down After Earnings Miss - Defense World
Here's What Important Indicators Reveal About BeOne Medicines Ltd.Sponsored ADR (ONC) Fourth Quarter Results - Bitget
Here's What Key Metrics Tell Us About BeOne Medicines Ltd.Sponsored ADR (ONC) Q4 Earnings - Yahoo Finance
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum - ChartMill
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
M&G PLC Has $41.17 Million Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Lowers Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Lowers Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
Bernstein Remains a Buy on BeOne Medicines AG (ONC) - Finviz
Candriam S.C.A. Sells 67,718 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 1,660 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Trial Wins And Sonrotoclax Clearance Meet Valuation Discount - Sahm
3 Stocks to Buy in February - Finviz
Beone Medicines Ltd Adr Azioni (ONC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Beone Medicines Ltd Adr Azioni (ONC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lee Chan Henry | SVP, General Counsel |
Apr 08 '26 |
Sale |
311.59 |
332 |
103,448 |
0 |
| Lee Chan Henry | SVP, General Counsel |
Mar 11 '26 |
Option Exercise |
191.64 |
341 |
65,348 |
341 |
| Lee Chan Henry | SVP, General Counsel |
Mar 11 '26 |
Sale |
300.00 |
341 |
102,300 |
0 |
| Lee Chan Henry | SVP, General Counsel |
Feb 04 '26 |
Option Exercise |
191.40 |
1,660 |
317,721 |
1,660 |
| Lee Chan Henry | SVP, General Counsel |
Feb 04 '26 |
Sale |
349.52 |
1,660 |
580,197 |
0 |
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):